About Hims
Hims is a company based in San Francisco (United States) founded in 2017 by Hilary Coles, Joe Spector, Andrew Dudum, and Jack Abraham. Hims has raised $197 million across 5 funding rounds from investors including Redpoint Ventures, Founders Fund and Forerunner Ventures. The company has 1,640 employees as of December 31, 2024. Hims has completed 8 acquisitions, including Apostrophe, Eucalyptus and Honest Health. Hims operates in a competitive market with competitors including Posterity Health, Opt Health, Healthemen, VitalityRx and Blokes, among others.
- Headquarter San Francisco, United States
- Employees 1640 as on 31 Dec, 2024
- Founders Hilary Coles, Joe Spector, Andrew Dudum, Jack Abraham
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hims & Hers Health, Inc.
-
Annual Revenue
$1.48 B (USD)69.33as on Dec 31, 2024
-
Net Profit
$126.04 M (USD)0as on Dec 31, 2024
-
EBITDA
$85.09 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$197 M (USD)
in 5 rounds
-
Latest Funding Round
$850 M (USD), Post-IPO
May 08, 2025
-
Investors
Redpoint Ventures
& 9 more
-
Employee Count
1640
as on Dec 31, 2024
-
Investments & Acquisitions
Apostrophe
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hims
Hims is a publicly listed company on the NYSE with ticker symbol HIMS in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Hims
Unlock access to complete
Unlock access to complete
Software Development Team
91 people
Operations Team
41 people
Leadership Team
30 people
Product Management Team
26 people
Data Analysis and Operations Team
24 people
Finance and Accounting
22 people
Creative and Marketing Team
15 people
Senior Team
11 people
Unlock access to complete
Funding Insights of Hims
Hims has successfully raised a total of $197M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $850 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Hims
Hims has secured backing from 10 investors, including venture fund investors. Prominent investors backing the company include Redpoint Ventures, Founders Fund and Forerunner Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Redpoint Ventures is engaged in venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital investments in technology and defense sectors.
|
Locked | Locked | Locked | |
|
Early-stage investments are directed toward tech startups by Forerunner Ventures.
|
Locked | Locked | Locked |
Investor details for Hims
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hims
Hims has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Apostrophe, Eucalyptus and Honest Health.
Investment portfolio details for Hims
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Patient empowerment, treatment, and support services are provided.
|
Locked | Locked | 2019 | Locked | |
|
Sterile medications are produced for hospitals and surgery centers.
|
Locked | Locked | 2019 | Locked | |
|
Blank check firm targeting mergers across multiple sectors.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Hims
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Hims
Detailed financials for Hims
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hims Comparisons
Peer comparison for Hims
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hims
Hims operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Posterity Health, Opt Health, Healthemen, VitalityRx and Blokes, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Virtual fertility consultations and treatments for men are offered.
|
|
| Locked | Locked | Locked |
Online teleconsultation platform for men's health services is provided.
|
|
| Locked | Locked | Locked |
Subscription-based healthcare for men including medications, diet, and fitness plans.
|
|
| Locked | Locked | Locked |
Online consultations for men's health and treatment plans are provided.
|
|
| Locked | Locked | Locked |
Telehealth service focused on men's health care.
|
Detailed competitors of Hims
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hims
Complete news archive for Hims
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hims
Hims was founded in 2017.
Hims is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Andrew Dudum is the current CEO of Hims. They have also founded this company.
Hims is a funded company, having raised a total of $197M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Hims is 1,640.
Annual revenue of Hims is $1.48B as on Dec 31, 2024.
Hims was founded in 2017 and is based in San Francisco, United States. An online telehealth platform is operated to address mens health needs, with services including treatments for hair loss, erectile dysfunction, and related conditions. Operations are conducted digitally, serving users primarily in the United States through consultations and prescription fulfillment.
Hims's top competitors include Posterity Health, Opt Health and VitalityRx.
Yes, Hims is publicly traded on NYSE under the ticker symbol HIMS.
Hims has made 8 acquisitions, including Apostrophe, Eucalyptus, and Honest Health.
Hims has 10 investors. Key investors include Redpoint Ventures, Founders Fund, Forerunner Ventures, 8VC, and IVP.
The ticker symbol of Hims is HIMS on NYSE.